Phase 1, open-label, multicenter study of sovleplenib (HMPL-523) in patients with relapsed or refractory lymphoma. // Blood Advances. – URL: https://www.sciencedirect.com/science/article/pii/S2473952926006671?dgcid=rss_sd_all
Phase 1, open-label, multicenter study of sovleplenib (HMPL-523) in patients with relapsed or refractory lymphoma. Blood Advances. https://www.sciencedirect.com/science/article/pii/S2473952926006671?dgcid=rss_sd_all
“Phase 1, open-label, multicenter study of sovleplenib (HMPL-523) in patients with relapsed or refractory lymphoma.” Blood Advances.
@article{article38199,
title = {Phase 1, open-label, multicenter study of sovleplenib (HMPL-523) in patients with relapsed or refractory lymphoma},
journal = {Blood Advances},
url = {https://www.sciencedirect.com/science/article/pii/S2473952926006671?dgcid=rss_sd_all}
}